Takeda Pharmaceutical Co Ltd (4502):企業の財務・戦略的SWOT分析

◆英語タイトル:Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C12051
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Takeda Pharmaceutical Co Ltd (4502) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.

Takeda Pharmaceutical Co Ltd Key Recent Developments

Dec 04,2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Dec 03,2018: Riassunto: Takeda presenter dati positivi da TOURMALINE-MM3, il primo studio pivot di fase 3 controllato con placebo per la valutazione di un trattamento con inibitore del proteasoma nell’ambito di una terapia di mantenimento
Dec 02,2018: Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
Dec 02,2018: Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
Nov 22,2018: Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Takeda Pharmaceutical Co Ltd – Key Facts 6
Takeda Pharmaceutical Co Ltd – Key Employees 7
Takeda Pharmaceutical Co Ltd – Key Employee Biographies 8
Takeda Pharmaceutical Co Ltd – Major Products and Services 9
Takeda Pharmaceutical Co Ltd – History 11
Takeda Pharmaceutical Co Ltd – Company Statement 27
Takeda Pharmaceutical Co Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Joint Venture 35
Section 2 – Company Analysis 37
Company Overview 37
Takeda Pharmaceutical Co Ltd – Business Description 38
Business Segment: Pharmaceutical Products 38
Overview 38
Performance 38
Geographical Segment: Asia 39
Performance 39
Geographical Segment: Europe and Canada 39
Performance 39
Geographical Segment: Japan 39
Performance 39
Geographical Segment: Latin America 39
Performance 39
Geographical Segment: Other 39
Performance 39
Geographical Segment: Russia/CIS 39
Performance 39
Geographical Segment: The US 39
Performance 39
Takeda Pharmaceutical Co Ltd – SWOT Analysis 40
SWOT Analysis – Overview 40
Takeda Pharmaceutical Co Ltd – Strengths 40
Takeda Pharmaceutical Co Ltd – Weaknesses 41
Takeda Pharmaceutical Co Ltd – Opportunities 42
Takeda Pharmaceutical Co Ltd – Threats 43
Takeda Pharmaceutical Co Ltd – Key Competitors 44
Section 3 – Company Financial Ratios 45
Financial Ratios – Capital Market Ratios 45
Financial Ratios – Annual Ratios 46
Performance Chart 49
Financial Performance 49
Financial Ratios – Interim Ratios 50
Financial Ratios – Ratio Charts 51
Section 4 – Company’s Lifesciences Financial Deals and Alliances 52
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53
Takeda Pharmaceutical Co Ltd, Recent Deals Summary 54
Section 5 – Company’s Recent Developments 55
Dec 04, 2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas 55
Dec 04, 2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas 57
Nov 21, 2018: Takeda gets conditional EC approval for $62bn Shire acquisition 59
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 60
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 62
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 64
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 66
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 68
Nov 01, 2018: Riassunto: Takeda presenter dati su una vasta gamma di esigenze di trattamento per i tumori del sangue al 60 congresso annuale dell’American Society of Hematology 70
Oct 31, 2018: Takeda reports second quarter FY2018 results 71
Section 6 – Appendix 73
Methodology 73
Ratio Definitions 73
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Takeda Pharmaceutical Co Ltd, Key Facts 6
Takeda Pharmaceutical Co Ltd, Key Employees 7
Takeda Pharmaceutical Co Ltd, Key Employee Biographies 8
Takeda Pharmaceutical Co Ltd, Major Products and Services 9
Takeda Pharmaceutical Co Ltd, History 11
Takeda Pharmaceutical Co Ltd, Other Locations 28
Takeda Pharmaceutical Co Ltd, Subsidiaries 29
Takeda Pharmaceutical Co Ltd, Joint Venture 35
Takeda Pharmaceutical Co Ltd, Key Competitors 44
Takeda Pharmaceutical Co Ltd, Ratios based on current share price 45
Takeda Pharmaceutical Co Ltd, Annual Ratios 46
Takeda Pharmaceutical Co Ltd, Annual Ratios (Cont...1) 47
Takeda Pharmaceutical Co Ltd, Annual Ratios (Cont...2) 48
Takeda Pharmaceutical Co Ltd, Interim Ratios 50
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53
Takeda Pharmaceutical Co Ltd, Recent Deals Summary 54
Currency Codes 73
Capital Market Ratios 73
Equity Ratios 74
Profitability Ratios 74
Cost Ratios 75
Liquidity Ratios 75
Leverage Ratios 76
Efficiency Ratios 76

List of Figures
Takeda Pharmaceutical Co Ltd, Performance Chart (2014 - 2018) 49
Takeda Pharmaceutical Co Ltd, Ratio Charts 51
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 53

★海外企業調査レポート[Takeda Pharmaceutical Co Ltd (4502):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CooperVision Inc:企業の製品パイプライン分析2018
    Summary CooperVision Inc (CooperVision), a subsidiary of The Cooper Companies Inc, designs and manufactures soft contact lenses. It manufactures a wide array of monthly, two-week and daily disposable contact lenses. CooperVision helps overcome various vision challenges such as astigmatism and presby …
  • Infosys Limited:戦略・SWOT・企業財務分析
    Infosys Limited - Strategy, SWOT and Corporate Finance Report Summary Infosys Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Nitto Denko Corporation:企業の戦略・SWOT・財務分析
    Nitto Denko Corporation - Strategy, SWOT and Corporate Finance Report Summary Nitto Denko Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sanderson Farms Inc:企業の戦略・SWOT・財務分析
    Sanderson Farms Inc - Strategy, SWOT and Corporate Finance Report Summary Sanderson Farms Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bactiguard Holding AB (BACTI B):医療機器:M&Aディール及び事業提携情報
    Summary Bactiguard Holding AB (Bactiguard) is a medical device manufacturer which develops and supplies infection protection solutions and antibiotics. The company’s product portfolio includes urinary catheters, foley catheters (BIP Foley catheters), endotracheal tubes and central venous catheters. …
  • Solvay SA (SOLB):電力:M&Aディール及び事業提携情報
    Summary Solvay SA (Solvay) is a chemical manufacturing company, which carries out production of specialty polymers, essential chemicals, silica and rare earth systems, consumer chemicals, polyamide and intermediates. In addition, the company manufactures additives, engineering plastics, diphenols an …
  • Parker Hannifin Corp (PH):企業の財務・戦略的SWOT分析
    Parker Hannifin Corp (PH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Isagen SA ESP-エネルギー分野:企業M&A・提携分析
    Summary Isagen SA ESP (Isagen), a subsidiary of Brookfield Renewable Energy Partners LP, is an electricity utility. It generates and markets electricity; supplies natural gas; and sells coal, steam, and other energy sources. The company produces electric energy from hydro and natural gas sources. Is …
  • TE Connectivity Ltd (TEL):企業の財務・戦略的SWOT分析
    TE Connectivity Ltd (TEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Airborne Tactical Advantage Company:企業の戦略・SWOT・財務情報
    Airborne Tactical Advantage Company - Strategy, SWOT and Corporate Finance Report Summary Airborne Tactical Advantage Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Dril-Quip Inc (DRQ):企業の財務・戦略的SWOT分析
    Dril-Quip Inc (DRQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Godrej Agrovet Limited (GODREJAGRO):企業の財務・戦略的SWOT分析
    Godrej Agrovet Limited (GODREJAGRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Titanium Metals Corporation:企業の戦略・SWOT・財務情報
    Titanium Metals Corporation - Strategy, SWOT and Corporate Finance Report Summary Titanium Metals Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • A1M Pharma AB (A1M)-製薬・医療分野:企業M&A・提携分析
    Summary A1M Pharma AB (A1M Pharma) develops and commercializes drug candidate for the diagnosis and treatment of pre-eclampsia (pandemic poisoning) and acute renal injury. The company offers ROSgard based on A1M (alpha-1-microglobulin), an endogenous protein with properties that captures and elimina …
  • Champions Oncology Inc (CSBR):企業の財務・戦略的SWOT分析
    Summary Champions Oncology Inc (Champions), formerly Champions Biotechnology Inc, is a developer of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s technology platform is an approach based upon the implantation of primary human tumor …
  • Medical Transcription Billing Corp (MTBC)-医療機器分野:企業M&A・提携分析
    Summary Medical Transcription Billing Corp (Medical Transcription) is a healthcare IT company that offers web-based solutions and related business services. The company offers electronic health records, practice management software, and patient engagement software. Its products comprise ChartsPro, P …
  • Seven Energy International Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Seven Energy International Ltd (Seven Energy) is an oil and gas company. The company explores, develops and distributes oil and gas interests. It provides crude oil and gas. Seven Energy offers upstream oil and gas, midstream gas processing and pipeline infrastructure services. The company’s …
  • Riemser Pharma GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Riemser Pharma GmbH (Riemser), formerly Riemser Arzneimittel AG is a healthcare products provider that markets and sells lifecycle management products. The company offers analgesics, cardiovascular products, over-the-counter medicines, prescription drugs and dental products. Its products inc …
  • Sucrerie Couplet SA:企業の戦略・SWOT・財務情報
    Sucrerie Couplet SA - Strategy, SWOT and Corporate Finance Report Summary Sucrerie Couplet SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Green Dot Corporation:企業の戦略・SWOT・財務分析
    Green Dot Corporation - Strategy, SWOT and Corporate Finance Report Summary Green Dot Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆